 FSD Pharma Inc CSE:HUGE, NASDAQ:HUGE revealed that it has received a study may proceed letter for its Investigational New Drug IND application from the US Food and Drug Administration FDA and notice of authorization from Health Canada for its Phase 2 clinical trial of FSD201. The Toronto-based biopharma firm said the corresponding study protocol is titled A Randomized, Double-Blind Placebo Controlled Parallel Group Study of Safety and Efficacy of FSD201 in Patients with Chronic Widespread Musculoskeletal Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome. 